CB-101 Phase 1 — Series A Plan

45 patients committed (Part A+B). 2→9 US sites (staggered). Part C optional. | Updated May 2026 — FDA PIND 181618 half-log escalation applied (B3: 21mg, B4: 50mg)

Committed (A+B)

At active dose

2→9

US sites (staggered)

M21

35 pts >=1mo (ISB-2001)

~$8.9M

Committed budget

Part C

Show +60 pts if triggered

Cohort Overview

Cohort	Part	Priming	Full Dose	Schedule	Active?	De Novo	Backfill	Total	Opens
A1	A	—	0.03 mg	Q2W		1	0	1	M0
A2	A	—	0.07 mg	Q2W		1	0	1	M1
A3	A	—	0.16 mg	Q2W		1	0	1	M2
A4	A	—	0.37 mg	Q2W		1	0	1	M3
A5	A	—	0.86 mg	Q2W		1	0	1	M4
A6	A	—	2.0 mg	Q2W		1	0	1	M5
B1	B	—	4 mg	Q2W		3	0	3	M8
B2	B	—	10 mg	Q2W	ACTIVE	3	6	9	M10
B3	B	—	21 mg	Q2W	ACTIVE	3	6	9	M12
B4	B	—	50 mg	Q2W	ACTIVE	3	6	9	M14
B5	B	—	100 mg	Q2W	ACTIVE	3	6	9	M16
Part C — Randomized (post-trigger M19). Not committed.
C1	C	2 mg	100 mg	Q2W	ACTIVE	—	—	20	M20+
C2	C	2 mg	21 mg	Q2W	ACTIVE	—	—	20	M20+
C3	C	2 mg	100 mg	Q4W	ACTIVE	—	—	20	M20+
Part A+B (committed)						15	24	45
+ Part C (if triggered)						—	—	60
Total A+B+C								105

Program Timeline (Gantt)

gantt
    title CB-101-001 Phase 1 Enrollment
    dateFormat YYYY-MM-DD
    axisFormat %b %y
    todayMarker off

    section Part A
    A1-A5 accelerated titration (6 pts) :a_all, 2027-06-01, 2027-12-01
    SRC review + priming :done, a_src, 2027-12-01, 2028-01-01
    section Part B
    B1 de novo (3 pts, 4mg) :b1_dn, 2028-02-01, 2028-03-01
    B2 de novo (3 pts, 10mg) :b2_dn, 2028-04-01, 2028-05-01
    B2 backfill (6 pts) :b2_bf, 2028-05-01, 2028-09-01
    B3 de novo (3 pts, 21mg) :b3_dn, 2028-06-01, 2028-07-01
    B3 backfill (6 pts) :b3_bf, 2028-07-01, 2029-02-01
    B4 de novo (3 pts, 50mg) :b4_dn, 2028-08-01, 2028-09-01
    B4 backfill (6 pts) :b4_bf, 2028-09-01, 2029-01-01
    B5 de novo (3 pts, 100mg) :b5_dn, 2028-10-01, 2028-11-01
    B5 backfill (6 pts) :b5_bf, 2028-11-01, 2029-04-01
    section Part C (Optional)
    Randomized dose optimisation (if activated) :crit, c_all, 2029-03-01, 180d
    section Milestones
    FPD :milestone, m_fpd, 2027-06-01, 0d
    ASH 2028 :milestone, m_ash, 2028-12-01, 0d
    ASCO 2029 :milestone, m_asco, 2029-06-01, 0d

Cumulative Enrollment by Cohort

Active Dose Patients & Follow-Up

Median Follow-Up (Active Dose)

Sites & Monthly Enrollment

Cash Position vs Data Maturity (Board View)

£5.7M

Cash at ASH 2028

12mo

Runway from ASH

£545K

Average Monthly Burn

£16.6M

Cash at FPD

£305K

Peak Monthly Burn

Cash Balance & Monthly Spend

Monthly Spend by Category

Cumulative Spend by Category

Budget Allocation

Full Budget Table

Date	Milestone	Salary	Consult	G&A	CMC	Trial	R&D	Total	Raise	Cash
Apr-26		£101K	£26K	£40K	£84K	—	£35K	£287K		£1.9M
May-26		£101K	£26K	£40K	£84K	—	£58K	£309K		£1.6M
Jun-26		£101K	£26K	£40K	£83K	—	£73K	£323K		£1.3M
Jul-26	Series A	£115K	£26K	£73K	£562K	—	£146K	£923K	£22.4M	£22.8M
Aug-26		£124K	£26K	£73K	£168K	—	£161K	£553K		£22.3M
Sep-26		£124K	£26K	£73K	£306K	—	£169K	£699K		£21.7M
Oct-26		£129K	£26K	£73K	£225K	—	£139K	£592K		£21.2M
Nov-26		£137K	£26K	£73K	£294K	—	£74K	£604K		£20.6M
Dec-26	MCB+Eng	£137K	£34K	£73K	£384K	—	£74K	£702K		£20.0M
Jan-27		£148K	£34K	£73K	£308K	—	£167K	£730K		£19.3M
Feb-27		£148K	£34K	£73K	£231K	—	£82K	£567K		£18.8M
Mar-27	IND	£148K	£34K	£73K	£344K	£80K	£82K	£761K		£18.1M
Apr-27		£148K	£32K	£73K	£258K	£20K	£82K	£612K		£17.6M
May-27		£148K	£29K	£73K	£144K	£42K	£82K	£519K		£17.1M
Jun-27	FPD	£148K	£39K	£73K	£37K	£266K	£89K	£651K		£16.6M
Jul-27		£148K	£39K	£73K	£37K	£110K	£82K	£488K		£16.1M
Aug-27		£148K	£39K	£73K	£37K	£110K	£82K	£488K		£15.7M
Sep-27		£148K	£39K	£73K	£37K	£152K	£82K	£529K		£15.2M
Oct-27		£152K	£39K	£73K	£37K	£178K	£82K	£560K		£14.7M
Nov-27		£152K	£39K	£73K	£37K	£157K	£82K	£539K		£14.2M
Dec-27		£152K	£39K	£73K	£37K	£66K	£83K	£449K		£13.8M
Jan-28	Part B	£152K	£39K	£73K	£31K	£478K	£35K	£807K		£13.1M
Feb-28		£152K	£39K	£73K	£31K	£87K	£35K	£416K		£12.7M
Mar-28	B2 Active	£152K	£40K	£73K	£31K	£398K	£50K	£743K		£12.0M
Apr-28		£152K	£40K	£73K	£14K	£358K	£35K	£672K		£11.4M
May-28		£152K	£40K	£73K	£14K	£472K	£35K	£786K		£10.6M
Jun-28		£152K	£40K	£73K	£14K	£508K	£35K	£821K		£9.8M
Jul-28		£152K	£40K	£73K	£14K	£472K	£35K	£786K		£9.1M
Aug-28	ASH Abs	£152K	£40K	£73K	£14K	£380K	£35K	£694K		£8.4M
Sep-28		£152K	£40K	£73K	£14K	£498K	£35K	£812K		£7.6M
Oct-28		£152K	£40K	£73K	£14K	£366K	£35K	£679K		£7.0M
Nov-28		£152K	£40K	£73K	£14K	£358K	£35K	£672K		£6.3M
Dec-28	ASH 2028	£152K	£40K	£73K	£14K	£380K	£35K	£694K		£5.7M
Jan-29		£152K	£40K	£73K	£5K	£265K	£35K	£571K		£5.1M
Feb-29	ISB=35	£152K	£40K	£73K	£5K	£180K	£35K	£485K		£4.6M
Mar-29		£152K	£40K	£73K	£5K	£106K	£50K	£427K		£4.2M
Apr-29		£152K	£40K	£73K	£5K	£117K	£35K	£422K		£3.8M
May-29		£152K	£40K	£73K	£5K	£76K	£35K	£381K		£3.5M
Jun-29	ASCO 2029	£152K	£40K	£73K	£5K	£242K	£35K	£548K		£2.9M
Jul-29		£152K	£40K	£73K	£5K	£76K	£35K	£381K		£2.6M
Aug-29		£152K	£40K	£73K	£5K	£76K	£35K	£381K		£2.2M
Sep-29		£152K	£40K	£73K	£5K	£118K	£35K	£423K		£1.8M
Oct-29		£152K	£40K	£73K	£5K	£84K	£35K	£389K		£1.4M
Nov-29		£152K	£40K	£73K	£5K	£76K	£35K	£381K		£1.0M
Dec-29		£152K	£40K	£73K	£5K	£76K	£35K	£381K		£632K
Jan-30		£152K	£40K	£73K	£5K	£76K	£35K	£381K		£253K
Feb-30		£152K	£40K	£73K	£5K	£84K	£35K	£389K		£-135K
Mar-30		£152K	£40K	£73K	£5K	£80K	£35K	£385K		£-520K
Apr-30		£152K	£40K	£73K	£5K	£76K	£35K	£381K		£-902K
May-30		£152K	£40K	£73K	£5K	—	£35K	£305K		£-1.2M
Jun-30		£152K	£40K	£73K	£5K	—	£35K	£305K		£-1.5M

Auto-generated from cb101-phase1-enrollment-projection.csv + coding-bio-company-budget.csv. Do not edit HTML directly.
Run: python3 tools/build_company_budget.py && python3 tools/build_enrollment_visual.py --password CodingBio2026! --open

CB-101 Dashboard

CB-101-001 Phase 1 — Series A Plan